Breaking through an epigenetic wall: Re-activation of Oct4 by KRAB-containing designer zinc finger transcription factors

Epigenetics

Volumn 8, Issue 2, 2013, Pages 164-176

  Juárez Moreno, Karla ^a,b   Erices, Rafaela ^a,c,d   Beltran, Adriana S ^a   Stolzenburg, Sabine ^a,e   Cuello Fredes, Mauricio ^c   Owen, Gareth I ^c   Qian, Haili ^a,f   Blancafort, Pilar ^a,e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d UNIVERSIDAD ANDRÉS BELLO   (Chile)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Artificial transcription factors; Breast cancer; DNA methylation; Epigenetics; KRAB domain; Oct4; Serous epithelial ovarian cancer; Zinc finger proteins

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; ZINC FINGER PROTEIN;

ARTICLE; BREAST CANCER; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENETIC TRANSDUCTION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; OVARY CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84874352327     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.23503     Document Type: Article

References (65)

1. Sterneckert J, Höing S, Schöler HR. Concise review: Oct4 and more: the reprogramming expressway. Stem Cells 2012; 30:15-21; PMID:22009686; http://dx.doi. org/10.1002/stem.765.
2. Walker E, Ohishi M, Davey RE, Zhang W, Cassar PA, Tanaka TS, et al. Prediction and testing of novel transcriptional networks regulating embryonic stem cell self-renewal and commitment. Cell Stem Cell 2007; 1:71-86; PMID:18371337; http://dx.doi. org/10.1016/j.stem.2007.04.002.
3. Liang J, Wan M, Zhang Y, Gu P, Xin H, Jung SY, et al. Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Nat Cell Biol 2008; 10:731-9; PMID:18454139; http://dx.doi. org/10.1038/ncb1736.
4. Pardo M, Lang B, Yu L, Prosser H, Bradley A, Babu MM, et al. An expanded Oct4 interaction network: implications for stem cell biology, development, and disease. Cell Stem Cell 2010; 6:382-95; PMID:20362542; http://dx.doi.org/10.1016/j. stem.2010.03.004.
5. Wang J, Rao S, Chu J, Shen X, Levasseur DN, Theunissen TW, et al. A protein interaction network for pluripotency of embryonic stem cells. Nature 2006; 444:364-8; PMID:17093407; http://dx.doi. org/10.1038/nature05284.
6. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122:947-56; PMID:16153702; http://dx.doi. org/10.1016/j.cell.2005.08.020.
7. Babaie Y, Herwig R, Greber B, Brink TC, Wruck W, Groth D, et al. Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. Stem Cells 2007; 25:500-10; PMID:17068183; http://dx.doi. org/10.1634/stemcells.2006-0426.
8. Feldman N, Gerson A, Fang J, Li E, Zhang Y, Shinkai Y, et al. G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat Cell Biol 2006; 8:188-94; PMID:16415856; http://dx.doi. org/10.1038/ncb1353.
9. Gu P, Xu X, Le Menuet D, Chung AC, Cooney AJ. Differential recruitment of methyl CpG-binding domain factors and DNA methyltransferases by the orphan receptor germ cell nuclear factor initiates the repression and silencing of Oct4. Stem Cells 2011; 29:1041-51; PMID:21608077; http://dx.doi. org/10.1002/stem.652.
10. Dyce PW, Toms D, Li J. Stem cells and germ cells: microRNA and gene expression signatures. Histol Histopathol 2010; 25:505-13; PMID:20183803.
11. Hassiotou F, Beltran A, Chetwynd E, Stuebe AM, Twigger AJ, Metzger P, et al. Breastmilk is a novel source of stem cells with multilineage differentiation potential. Stem Cells 2012; 30:2164-74; PMID:22865647; http://dx.doi.org/10.1002/stem.1188.
12. Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP, et al. Generation of tumorinitiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res 2011; 13:R94; PMID:21952072; http://dx.doi.org/10.1186/bcr3019.
13. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, et al. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 2012; 7:e46858; PMID:23056490; http://dx.doi.org/10.1371/journal. pone.0046858.
14. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ. Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol 2010; 63:879-83; PMID:20876318; http://dx.doi.org/10.1136/ jcp.2009.073593.
15. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-72; PMID:18035408; http://dx.doi. org/10.1016/j.cell.2007.11.019.
16. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-76; PMID:16904174; http://dx.doi.org/10.1016/j. cell.2006.07.024.
17. Kim JB, Greber B, Araúzo-Bravo MJ, Meyer J, Park KI, Zaehres H, et al. Direct reprogramming of human neural stem cells by OCT4. Nature 2009; 461:649-3; PMID:19718018; http://dx.doi.org/10.1038/ nature08436.
18. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007; 448:318-24; PMID:17554336; http://dx.doi. org/10.1038/nature05944.
19. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467:285-90; PMID:20644535; http:// dx.doi.org/10.1038/nature09342.
20. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471:68-73; PMID:21289626; http:// dx.doi.org/10.1038/nature09798.
21. Shi Y, Desponts C, Do JT, Hahm HS, Schöler HR, Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with smallmolecule compounds. Cell Stem Cell 2008; 3:568-74; PMID:18983970; http://dx.doi.org/10.1016/j. stem.2008.10.004.
22. Feng B, Ng JH, Heng JC, Ng HH. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009; 4:301-12; PMID:19341620; http://dx.doi. org/10.1016/j.stem.2009.03.005.
23. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008; 26:1269-75; PMID:18849973; http://dx.doi.org/10.1038/ nbt.1502.
24. Doege CA, Inoue K, Yamashita T, Rhee DB, Travis S, Fujita R, et al. Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature 2012; 488:652-5; PMID:22902501; http:// dx.doi.org/10.1038/nature11333.
25. Bhutani N, Brady JJ, Damian M, Sacco A, Corbel SY, Blau HM. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 2010; 463:1042-7; PMID:20027182; http://dx.doi. org/10.1038/nature08752.
26. Bultmann S, Morbitzer R, Schmidt CS, Thanisch K, Spada F, Elsaesser J, et al. Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res 2012; 40:5368-77; PMID:22387464; http://dx.doi.org/10.1093/nar/ gks199.
27. Beltran AS, Blancafort P. Remodeling genomes with artificial transcription factors (ATFs). Methods Mol Biol 2010; 649:163-82; PMID:20680834; http:// dx.doi.org/10.1007/978-1-60761-753-2-10.
28. de Groote ML, Verschure PJ, Rots MG. Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res 2012; 40:10596-613; PMID:23002135; http://dx.doi.org/10.1093/nar/gks863.
29. Blancafort P, Segal DJ, Barbas CF 3rd. Designing transcription factor architectures for drug discovery. Mol Pharmacol 2004; 66:1361-71; PMID:15340042; http://dx.doi.org/10.1124/mol.104.002758.
30. Beltran AS, Blancafort P. Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics 2011; 6:224-35; PMID:20948306; http://dx.doi. org/10.4161/epi.6.2.13700.
31. Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW, et al. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 2007; 26:2791-8; PMID:17057734; http://dx.doi.org/10.1038/sj.onc.1210072.
32. Beltran AS, Russo A, Lara H, Fan C, Lizardi PM, Blancafort P. Suppression of breast tumor growth and metastasis by an engineered transcription factor. PLoS One 2011; 6:e24595; PMID:21931769; http://dx.doi. org/10.1371/journal.pone.0024595.
33. Lara H, Wang Y, Beltran AS, Juárez-Moreno K, Yuan X, Kato S, et al. Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J Biol Chem 2012; 287:29873-86; PMID:22782891; http://dx.doi.org/10.1074/jbc.M112.360768.
34. Beltran AS, Sun X, Lizardi PM, Blancafort P. Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther 2008; 7:1080-90; PMID:18483297; http://dx.doi. org/10.1158/1535-7163.MCT-07-0526.
35. Sera T. Zinc-finger-based artificial transcription factors and their applications. Adv Drug Deliv Rev 2009; 61:513-26; PMID:19394375; http://dx.doi. org/10.1016/j.addr.2009.03.012.
36. Blancafort P, Beltran AS. Rational design, selection and specificity of artificial transcription factors (ATFs): the influence of chromatin in target gene regulation. Comb Chem High Throughput Screen 2008; 11:146-58; PMID:18336208; http://dx.doi. org/10.2174/138620708783744453.
37. Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res 2012; 40:6725-40; PMID:22561374; http://dx.doi.org/10.1093/nar/ gks360.
38. Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, Strahl BD, et al. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics 2012; 7:350-60; PMID:22419067; http:// dx.doi.org/10.4161/epi.19507.
39. Iyengar S, Farnham PJ. KAP1 protein: an enigmatic master regulator of the genome. J Biol Chem 2011; 286:26267-76; PMID:21652716; http://dx.doi. org/10.1074/jbc.R111.252569.
40. Iyengar S, Ivanov AV, Jin VX, Rauscher FJ 3rd, Farnham PJ. Functional analysis of KAP1 genomic recruitment. Mol Cell Biol 2011; 31:1833-47; PMID:21343339; http://dx.doi.org/10.1128/MCB.01331-10.
41. Frietze S, Lan X, Jin VX, Farnham PJ. Genomic targets of the KRAB and SCAN domain-containing zinc finger protein 263. J Biol Chem 2010; 285:1393-403; PMID:19887448; http://dx.doi.org/10.1074/jbc. M109.063032.
42. Meilinger D, Fellinger K, Bultmann S, Rothbauer U, Bonapace IM, Klinkert WE, et al. Np95 interacts with de novo DNA methyltransferases, Dnmt3a and Dnmt3b, and mediates epigenetic silencing of the viral CMV promoter in embryonic stem cells. EMBO Rep 2009; 10:1259-64; PMID:19798101; http://dx.doi. org/10.1038/embor.2009.201.
43. Epsztejn-Litman S, Feldman N, Abu-Remaileh M, Shufaro Y, Gerson A, Ueda J, et al. De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes. Nat Struct Mol Biol 2008; 15:1176-83; PMID:18953337; http:// dx.doi.org/10.1038/nsmb.1476.
44. Hochedlinger K, Plath K. Epigenetic reprogramming and induced pluripotency. Development 2009; 136:509-23; PMID:19168672; http://dx.doi. org/10.1242/dev.020867.
45. Kim JB, Zaehres H, Wu G, Gentile L, Ko K, Sebastiano V, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008; 454:646-50; PMID:18594515; http:// dx.doi.org/10.1038/nature07061.
46. Kobolak J, Kiss K, Polgar Z, Mamo S, Rogel-Gaillard C, Tancos Z, et al. Promoter analysis of the rabbit POU5F1 gene and its expression in preimplantation stage embryos. BMC Mol Biol 2009; 10:88; PMID:19732419; http://dx.doi.org/10.1186/1471-2199-10-88.
47. Beerli RR, Segal DJ, Dreier B, Barbas CF 3rd. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc Natl Acad Sci U S A 1998; 95:14628-33; PMID:9843940; http://dx.doi.org/10.1073/ pnas.95.25.14628.
48. Urrutia R. KRAB-containing zinc-finger repressor proteins. Genome Biol 2003; 4:231; PMID:14519192; http://dx.doi.org/10.1186/gb-2003-4-10-231.
49. Collins T, Stone JR, Williams AJ. All in the family: the BTB/POZ, KRAB, and SCAN domains. Mol Cell Biol 2001; 21:3609-15; PMID:11340155; http://dx.doi. org/10.1128/MCB.21.11.3609-3615.2001.
50. Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem celllike cells in ovarian cancer. Oncogene 2010; 29:2153-9; PMID:20101213; http://dx.doi.org/10.1038/ onc.2009.500.
51. Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Mol Cell Biol 2005; 25:1100-12; PMID:15657436; http://dx.doi.org/10.1128/ MCB.25.3.1100-1112.2005.
52. Tachibana M, Matsumura Y, Fukuda M, Kimura H, Shinkai Y. G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription. EMBO J 2008; 27:2681-90; PMID:18818694; http:// dx.doi.org/10.1038/emboj.2008.192.
53. Hu T, Liu S, Breiter DR, Wang F, Tang Y, Sun S. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res 2008; 68:6533-40; PMID:18701476; http://dx.doi.org/10.1158/0008-5472.CAN-07-6642.
54. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010; 29:2672-80; PMID:20190812; http://dx.doi. org/10.1038/onc.2010.35.
55. Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 2010; 102:1276-83; PMID:20354527; http://dx.doi.org/10.1038/ sj.bjc.6605626.
56. Samardzija C, Quinn M, Findlay JK, Ahmed N. Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. J Ovarian Res 2012; 5:37; PMID:23171809; http://dx.doi. org/10.1186/1757-2215-5-37.
57. Mak VC, Siu MK, Wong OG, Chan KK, Ngan HY, Cheung AN. Dysregulated stemness-related genes in gynecological malignancies. Histol Histopathol 2012; 27:1121-30; PMID:22806899.
58. Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 2010; 177:1087-94; PMID:20671266; http://dx.doi.org/10.2353/ ajpath.2010.100316.
59. Gentilini O, Masullo M, Rotmensz N, Peccatori F, Mazzarol G, Smeets A, et al. Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options. Eur J Surg Oncol 2005; 31:232-6; PMID:15780556; http://dx.doi.org/10.1016/j. ejso.2004.11.012.
60. Keleher AJ, Theriault RL, Gwyn KM, Hunt KK, Stelling CB, Singletary SE, et al. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg 2002; 194:54-64; PMID:11800340; http://dx.doi.org/10.1016/S1072-7515(01)01105-X.
61. Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ 3rd. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev 2002; 16:919-32; PMID:11959841; http://dx.doi. org/10.1101/gad.973302.
62. Yu HB, Kunarso G, Hong FH, Stanton LW. Zfp206, Oct4, and Sox2 are integrated components of a transcriptional regulatory network in embryonic stem cells. J Biol Chem 2009; 284:31327-35; PMID:19740739; http://dx.doi.org/10.1074/jbc.M109.016162.
63. Zaret KS, Carroll JS. Pioneer transcription factors: establishing competence for gene expression. Genes Dev 2011; 25:2227-41; PMID:22056668; http:// dx.doi.org/10.1101/gad.176826.111.
64. Wang ZX, Teh CH, Chan CM, Chu C, Rossbach M, Kunarso G, et al. The transcription factor Zfp281 controls embryonic stem cell pluripotency by direct activation and repression of target genes. Stem Cells 2008; 26:2791-9; PMID:18757296; http://dx.doi. org/10.1634/stemcells.2008-0443.
65. Mandell JG, Barbas CF 3rd. Zinc Finger Tools: custom DNA-binding domains for transcription factors and nucleases. Nucleic Acids Res 2006; 34(Web Server issue):W516-23; PMID:16845061; http://dx.doi. org/10.1093/nar/gkl209.